Synapse Open Synapse
Biology

Keytruda biosimilars are coming — but they face an uphill battle

BioPharma Dive · · 4 min read

A patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.

Latest from BioPharma Dive